Viridian Therapeutics, Inc.\DE
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
VRDN$30.86+2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
| September 30,2026 | December 31,2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $172,860 | $212,382 |
| Restricted cash | 1,300 | — |
| Marketable securities | 782,346 | 662,270 |
| Accounts receivable, net | 29,782 | — |
| Inventory | 85 | — |
| Prepaid expenses and other current assets | 26,757 | 19,581 |
| Total current assets | 1,013,130 | 894,233 |
| Property and equipment, net | 2,972 | 1,228 |
| Operating lease right-of-use asset | 2,645 | 2,421 |
| Intangible asset, net | 9,792 | — |
| Other assets | 131 | 1,536 |
| Total assets | $1,028,670 | $899,418 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $9,297 | $8,683 |
| Accrued liabilities | 60,756 | 62,013 |
| Total current liabilities | 70,053 | 70,696 |
| Long-term debt, net | — | 49,940 |
| Derivative liability | 11,620 | 20,030 |
| Liability related to the sale of future revenue, net | 121,608 | 34,244 |
| Convertible notes, net | 242,461 | — |
| Other liabilities | 2,230 | 2,341 |
| Total liabilities | 447,972 | 177,251 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity: | ||
| Preferred stock, series A non-voting convertible preferred stock, $0.01 par value; 435,000 shares authorized; 133,191 and 134,864 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 60,432 | 61,188 |
| Preferred stock, series B non-voting convertible preferred stock, $0.01 par value; 500,000 shares authorized; 48,463 and 79,620 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 37,592 | 70,868 |
| Common stock, $0.01 par value; 200,000,000 shares authorized; 113,525,222 and 101,826,500 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 1,135 | 1,018 |
| Additional paid-in capital | 2,155,427 | 1,927,104 |
| Accumulated other comprehensive income (loss) | (2,201) | 447 |
| Accumulated deficit | (1,671,687) | (1,338,458) |
| Total stockholders’ equity | 580,698 | 722,167 |
| Total liabilities and stockholders’ equity | $1,028,670 | $899,418 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.